Literature DB >> 7642551

FK506 binding protein mutational analysis. Defining the surface residue contributions to stability of the calcineurin co-complex.

O Futer1, M T DeCenzo, R A Aldape, D J Livingston.   

Abstract

The 12- and 13-kDa FK506 binding proteins (FKBP12 and FKBP13) are cis-trans peptidyl-prolyl isomerases that bind the macrolides FK506 (Tacrolimus) and rapamycin (Sirolimus). The FKBP12.FK506 complex is immunosuppressive, acting as an inhibitor of the protein phosphatase calcineurin. We have examined the role of the key surface residues of FKBP12 and FKBP13 in calcineurin interactions by generating substitutions at these residues by site-directed mutagenesis. All mutants are active catalysts of the prolyl isomerase reaction, and bind FK506 or rapamycin with high affinity. Mutations at FKBP12 residues Asp-37, Arg-42, His-87, and Ile-90 decrease calcineurin affinity of the mutant FKBP12.FK506 complex by as much as 2600-fold in the case of I90K. Replacement of three FKBP13 surface residues (Gln-50, Ala-95, and Lys-98) with the corresponding homologous FKBP12 residues (Arg-42, His-87, and Ile-90) generates an FKBP13 variant that is equivalent to FKBP12 in its affinity for FK506, rapamycin, and calcineurin. These results confirm the role of two loop regions of FKBP12 (residues 40-44 and 84-91) as part of the effector face that interacts with calcineurin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7642551     DOI: 10.1074/jbc.270.32.18935

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Practical applications of time-averaged restrained molecular dynamics to ligand-receptor systems: FK506 bound to the Q50R,A95H,K98I triple mutant of FKBP-13.

Authors:  C A Lepre; D A Pearlman; O Futer; D J Livingston; J M Moore
Journal:  J Biomol NMR       Date:  1996-07       Impact factor: 2.835

2.  The wheat peptidyl prolyl cis-trans-isomerase FKBP77 is heat induced and developmentally regulated.

Authors:  I Kurek; K Aviezer; N Erel; E Herman; A Breiman
Journal:  Plant Physiol       Date:  1999-02       Impact factor: 8.340

3.  Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor.

Authors:  Robert J Bastidas; Cecelia A Shertz; Soo Chan Lee; Joseph Heitman; Maria E Cardenas
Journal:  Eukaryot Cell       Date:  2011-12-30

Review 4.  Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach.

Authors:  Praveen R Juvvadi; Soo Chan Lee; Joseph Heitman; William J Steinbach
Journal:  Virulence       Date:  2016-06-20       Impact factor: 5.882

5.  Creating diverse target-binding surfaces on FKBP12: synthesis and evaluation of a rapamycin analogue library.

Authors:  Xianghong Wu; Lisheng Wang; Yaohua Han; Nicholas Regan; Pui-Kai Li; Miguel A Villalona; Xiche Hu; Roger Briesewitz; Dehua Pei
Journal:  ACS Comb Sci       Date:  2011-07-28       Impact factor: 3.784

6.  Mechanism of TGFbeta receptor inhibition by FKBP12.

Authors:  Y G Chen; F Liu; J Massague
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

7.  Biochemical and genetic characterization of an FK506-sensitive peptidyl prolyl cis-trans isomerase from a thermophilic archaeon, Methanococcus thermolithotrophicus.

Authors:  M Furutani; T Iida; S Yamano; K Kamino; T Maruyama
Journal:  J Bacteriol       Date:  1998-01       Impact factor: 3.490

8.  Inhibition and Substrate Specificity Properties of FKBP22 from a Psychrotrophic Bacterium, Shewanella sp. SIB1.

Authors:  Cahyo Budiman; Herman Umbau Lindang; Bo Eng Cheong; Kenneth F Rodrigues
Journal:  Protein J       Date:  2018-06       Impact factor: 2.371

9.  Analysis of calstabin2 (FKBP12.6)-ryanodine receptor interactions: rescue of heart failure by calstabin2 in mice.

Authors:  Fannie Huang; Jian Shan; Steven Reiken; Xander H T Wehrens; Andrew R Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-15       Impact factor: 11.205

10.  Structure comparison of native and mutant human recombinant FKBP12 complexes with the immunosuppressant drug FK506 (tacrolimus).

Authors:  S Itoh; M A Navia
Journal:  Protein Sci       Date:  1995-11       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.